Análise da evolução da qualidade de vida, performance-status, teste de caminhada de seis minutos e índice de massa corpórea em pacientes com câncer de pulmão avançado submetidos à quimioterapia / Analysis of evolution of quality of life, performance status, body mass index and six minute walk test in patients with advanced lung cancer

AUTOR(ES)
DATA DE PUBLICAÇÃO

2010

RESUMO

Lung cancer (LC), one of the most common types of cancer, is a serious public health problem and responsible for a higher number of mortality. Most of the patients are in advanced stage of disease at presentation. Chemotherapy is the most appropriate treatment for this patient profile. However treatment is often accompanied by side effects that may directly interfere in functional capabilities and the quality of life (QoL) of patients. The aim of this study was to evaluate the effect of chemotherapy on the physical condition and QoL of patients with advanced LC. We evaluated 50 patients with non-small cell lung cancer (NSCLC) in stage IIIB and IV and performance status ECOG-PS between zero and two. All received chemotherapy drugs paclitaxel and platinum derivatives, and were evaluated in three stages: pre-chemotherapy, after-chemotherapy and six after six treatment initiation. We evaluated the ECOG-PS and the index, body mass index (BMI) and six minutes walk test (6MWT) and QoL by SF-36, EORTC QLQ C-30 along with your module LC13 and hospital anxiety and depression scale (HAD). Thirty one patients completed the study after six months. At progression, 19 died or deteriorated ECOG-PS. The SF-36 showed no statistical significance in any of the fields, the EORTC-C30 showed improvement in social and insomnia, and worsening for the symptom nausea, the LC13, his symptoms improved dyspnea, cough, hemoptysis, pain and alopecia chest, but worsening of peripheral neuropathy and by the application of HAD patients did not have anxiety and depression. There was no statistically significant difference between assessments for BMI, the 6MWT did not show statistically significant difference in any of the evaluated time. Regarding EGOG, there was a benefit of chemotherapy, mainly in the increase of asymptomatic patients after six months of follow up (p = 0.031). It is concluded that there was benefit from the use of chemotherapy in relation to the improvement of PS. The assessment of BMI and 6MWT did not change during the study, which may suggest maintenance of physical condition. QoL also showed no evidence of worsening or improvement

ASSUNTO(S)

qualidade de vida quimioterapia neoplasias pulmonares tolerância ao exercício quality of life chemotherapy lung neoplasms exercise tolerance

ACESSO AO ARTIGO

Documentos Relacionados